KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

-The Economic Times Rajan Mittal resigned as director of Bharti Retail last November, barely weeks after the Enforcement Directorate launched a probe into a controversial $100-million investment by Walmart Stores in Cedar Support Services, the holding company of the retail venture. A Bharti spokesman said Mittal had resigned from the board last year to "take out time for his other commitments" and has been replaced by Bharti Group's general counsel and...

-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...

-Outlook India has long been the sleeping giant of global agriculture. But its misguided policies while boosting short-term output, yet may transform India into a food importer After decades on the sidelines of international agricultural trade, India was poised last year to become a major food supplier, overtaking traditional exporters of food grain and meat. This could prove to be flash in the pan. The sudden rise and fall of India...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...